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Background: Dyspnea is very frequent in obese subjects. However, its assessment is complex in clinical practice.
The modified Medical Research Council scale (mMRC scale) is largely used in the assessment of dyspnea in chronic
respiratory diseases, but has not been validated in obesity. The objectives of this study were to evaluate the use of
the mMRC scale in the assessment of dyspnea in obese subjects and to analyze its relationships with the 6-minute
walk test (6MWT), lung function and biological parameters.
Methods: Forty-five obese subjects (17 M/28 F, BMI: 43 ± 9 kg/m2) were included in this pilot study. Dyspnea in
daily living was evaluated by the mMRC scale and exertional dyspnea was evaluated by the Borg scale after 6MWT.
Pulmonary function tests included spirometry, plethysmography, diffusing capacity of carbon monoxide and arterial
blood gases. Fasting blood glucose, total cholesterol, triglyceride, N-terminal pro brain natriuretic peptide, C-reactive
protein and hemoglobin levels were analyzed.
Results: Eighty-four percent of patients had a mMRC≥ 1 and 40% a mMRC≥ 2. Compared to subjects with no
dyspnea (mMRC= 0), a mMRC≥ 1 was associated with a higher BMI (44 ± 9 vs 36 ± 5 kg/m2, p = 0.01), and a lower
expiratory reserve volume (ERV) (50 ± 31 vs 91 ± 32%, p = 0.004), forced expiratory volume in one second (FEV1)
(86 ± 17 vs 101 ± 16%, p = 0.04) and distance covered in 6MWT (401 ± 107 vs 524 ± 72 m, p = 0.007). A mMRC≥ 2
was associated with a higher Borg score after the 6MWT (4.7 ± 2.5 vs 6.5 ± 1.5, p < 0.05).
Conclusion: This study confirms that dyspnea is very frequent in obese subjects. The differences between the
“dyspneic” and the “non dyspneic” groups assessed by the mMRC scale for BMI, ERV, FEV1 and distance covered in
6MWT suggests that the mMRC scale might be an useful and easy-to-use tool to assess dyspnea in daily living in
obese subjects.
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Obesity, defined as a Body Mass Index (BMI) greater
than or equal to 30 kg/m2, is a significant public health
concern. According to the World Health Organization,
worldwide obesity has more than doubled since 1980
and in 2008 there were about 1.5 billion overweight
adults (25 ≤BMI < 30 kg/m2). Of these, over 200 million
men and nearly 300 million women were obese [1].* Correspondence: launois.claire@gmail.com
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reproduction in any medium, provided the orDyspnea is very frequent in obese subjects. In a large
epidemiological study, 80% of obese patients reported
dyspnea after climbing two flights of stairs [2]. In a
series of patients with morbid obesity, Collet et al. found
that patients with a BMI > 49 kg/m2 had more severe
dyspnea assessed with BDI (Baseline Dyspnea Index)
than obese patients with a BMI ≤ 49 kg/m2 [3]. The most
frequent pulmonary function abnormalities associated
with obesity [4,5] are a decrease in expiratory reserve
volume (ERV) [6-8], functional residual capacity (FRC)
[6-8], and an increase in oxygen consumption [9]. Al-
though the mechanisms of dyspnea in obesity remainl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 The modified Medical Research Council (mMRC)
scale
Grade Description of Breathlessness
Grade 0 I only get breathless with strenuous exercise
Grade 1 I get short of breath when hurrying on level
ground or walking up a slight hill
Grade 2 On level ground, I walk slower than people of the
same age because of breathlessness, or I have to stop
for breath when walking at my own pace on the level
Grade 3 I stop for breath after walking about 100 yards or
after a few minutes on level ground
Grade 4 I am too breathless to leave the house or
I am breathless when dressing
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[3,10-16]. Of note, type 2 diabetes [17], insulin resistance
[18] and metabolic syndrome [19] have been shown to
be associated with reduced lung function in obesity. It
must be pointed out that dyspnea is a complex subject-
ive sensation which is difficult to assess in clinical prac-
tice. However, there is no specific scale to assess
dyspnea in daily living in obesity. The modified Medical
Research Council (mMRC) scale is the most commonly
used validated scale to assess dyspnea in daily living in
chronic respiratory diseases [20-22] but has never been
assessed in the context of obesity without a coexisting
pulmonary disease.
The objectives of this pilot study were to evaluate the
use of the mMRC scale in the assessment of dyspnea in
obese subjects and to analyze its relationships with the




Adult obese patients from the Department of Nutrition
of the University Hospital of Reims (France) were con-
secutively referred for a systematic respiratory evaluation
without specific reason and considered for inclusion in
this study. Inclusion criteria were a BMI ≥ 30 kg/m2 and
an age > 18 year-old. Exclusion criteria were a known
coexisting pulmonary or neuromuscular disease or an
inability to perform a 6MWT or pulmonary function
testing. The study was approved by the Institutional Re-
view Board (IRB) of the University Hospital of Reims,
and patient consent was waived.
Methods
Clinical characteristics and mMRC scale
Demographic data (age, sex), BMI, comorbidities, treat-
ments and smoking status were systematically recorded.
Dyspnea in daily living was evaluated by the mMRC
scale which consists in five statements that describe al-
most the entire range of dyspnea from none (Grade 0)
to almost complete incapacity (Grade 4) (Table 1).
Six-minute walk test
The 6MWT was performed using the methodology spe-
cified by the American Thoracic Society (ATS-2002)
[23]. The patients were instructed that the objective was
to walk as far as possible during 6 minutes. The 6MWT
was performed in a flat, long, covered corridor which
was 30 meters long, meter-by-meter marked. Heart rate,
oxygen saturation and modified Borg scale assessing
subjectively the degree of dyspnea graded from 0 to 10,
were collected at the beginning and at the end of the
6MWT. When the test was finished, the distance cov-
ered was calculated.Pulmonary function tests
Pulmonary function tests (PFTs) included forced expira-
tory volume in one second (FEV1), vital capacity (VC),
forced vital capacity (FCV), FEV1/VC, functional re-
sidual capacity (FRC), expiratory reserve volume (ERV),
residual volume (RV), total lung capacity (TLC) and car-
bon monoxide diffusing capacity of the lung (DLCO)
(BodyBox 5500 Medisoft Sorinnes, Belgium). Results
were expressed as the percentage of predicted values
[24]. Arterial blood gases were measured in the morning
in a sitting position.
Biological parameters
After 12 hours of fasting, blood glucose, glycated
hemoglobin (HbAIc), total cholesterol, triglyceride, N-
terminal pro brain natriuretic peptide (NT-pro BNP), C-
reactive protein (CRP) and hemoglobin levels were
measured.
Statistical analysis
Quantitative variables are described as mean ± standard
deviation (SD) and qualitative variables as number and
percentage. Patients were separated in two groups
according to their dyspnea: mMRC=0 (no dyspnea in
daily living) and mMRC ≥ 1 (dyspnea in daily living, ie at
least short of breath when hurrying on level ground or
walking up a slight hill).
Factors associated with mMRC scale were studied
using Wilcoxon, Chi-square or Fisher exact tests. Factors
associated with Borg scale were studied using Wilcoxon
tests or Pearson’s correlation coefficients. A p value <
0.05 was considered statistically significant. All analysis




Fifty four consecutive patients with a BMI≥ 30 kg/m2
were considered for inclusion. Of these, 9 patients were
Table 3 Dyspnea assessment of the 45 adult obese
patients
Total (n = 45)
mMRC scale (0-4) 1.4 ± 0,9
mMRC scale≥ 1 38 (84%)
mMRC scale≥ 2 18 (40%)
Borg scale at rest (1-10) 1 ± 1,5
Borg scale at rest≥ 1 25 (56%)
Borg scale after 6MWT (1-10) 5.4 ± 2.4
Borg scale after 6MWT≥ 5 24 (53%)
Data are expressed as mean ± SD or number (%).
mMRC: modified Medical Research Council, 6MWT: six-minute walk test.
Table 4 Functional characteristics of the 45 adult obese
patients
Total (n = 45)
Spirometry (n = 45)
FEV1,% pred 88 ± 18
VC,% pred 92 ± 20
FEV1 < 80% 13 (29%)
FEV1/VC 0.77 ± 0.10
FEV1/ VC< 0.7 5 (11%)
Plethysmography (n = 38)
FRC,% pred 94 ± 23
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related to an osteoarticular disorder (n = 2) or because of
a diagnosed respiratory disease (n = 7; 5 asthma, 1 hyper-
sensitivity pneumonia and 1 right pleural effusion).
Results of 45 patients were considered in the final ana-
lysis. Demographic characteristics of the patients are
presented in Table 2. Mean BMI was 43 ± 9 kg/m2, with
55% of the patients presenting an extreme obesity
(BMI ≥ 40 kg/m2, grade 3). Regarding smoking status,
56% of patients were never smokers and 11% were
current smokers. The main comorbidities were hyper-
tension (53%), dyslipidemia (40%) and diabetes (36%).
Severe obstructive sleep apnea syndrome was present in
16 patients (43%).
Dyspnea assessment by the mMRC scale and 6MWT
Results of dyspnea assessment are presented in Table 3.
Dyspnea symptom assessed by the mMRC scale was very
frequent in obese subjects with 84% (n = 38) of patients
with a mMRC scale ≥ 1 and 40% (n = 18) of patients with
a mMRC scale ≥ 2 (29% mMRC=2, 9% mMRC=3 and
2% mMRC=4).
The mean distance covered in 6MWT was
420 ± 112 m. Sixteen percent of patients had a decrease >
4% of SpO2 during the 6MWT and one patient had a
SpO2 < 90% at the end of the 6MWT (Table 4). The dys-
pnea sensation at rest was very slight (Borg = 1 ± 1.5) but
severe after exertion (Borg = 5.4 ± 2.4). Fifty-three per-
cent of patients exhibited a Borg scale ≥ 5 after the
6MWT which is considered as severe exertionalTable 2 Clinical characteristics of the 45 adult obese
patients
Total (n = 45)
Age 51 ± 11
Sex (M/F) 17/28
BMI (kg/m2) 43 ± 9
30≤ BMI < 35 (kg/m2) (grade 1) 7 (16%)
35≤ BMI < 40 (kg/m2) (grade 2) 13 (29%)










Apnea/hypopnea index scores (n/h) (n = 35) 28 ± 20
Data are expressed as mean ± SD or number (%).dyspnea. No complication occurred during the 6MWT.
Subjects with a mMRC score ≥ 2 had a higher Borg score
after the 6MWT than subjects with a mMRC score < 2
(6.5 ± 1.5 vs 4.7 ± 2.5, p < 0.05).ERV,% pred 56 ± 34
TLC,% pred 98 ± 17
TLC< 80% 5 (13%)
DLCO,% pred 83 ± 18
DLCO< 70% 10 (26%)
Arterial blood gases (n = 43)
pH 7.42 ± 0,03
PaO2 (mmHg) 90 ± 16
PaO2≤ 70 mmHg 0 (0%)
PaCO2 (mmHg) 39 ± 4
PaCO2> 45 mmHg 0 (0%)
Walking test (n = 45)
6-minute walk distance (m) 420± 112
SpO2 at rest (%) 97 ± 2
SpO2 after 6MWT (%) 95 ± 2
Decrease > 4% of SpO2 7 (16%)
SpO2 after 6MWT< 90% 1 (2%)
Data are expressed as mean ± SD or number (%).
FEV1: expiratory volume in one second, VC: vital capacity, FRC: functional
residual capacity, ERV: expiratory reserve volume, TLC: total lung capacity,
DLCO: carbon monoxide diffusing capacity of the lung, pred: predicted value,
6MWT: six-minute walk test.
Table 5 Comparisons of patients with mMRC=0 and
patients with mMRC≥ 1 concerning clinical
characteristics, lung function and biological parameters
MRC=0 (n = 7) MRC≥ 1 (n = 38)
Demographic characteristics
Age 50 ± 10 51 ± 11
Sex (M/F) 4/3 13/25
BMI (kg/m2) 36 ± 5 44± 9*
Smoking history
Pack-years 10 ± 16 10 ± 17
PFTs
FEV1,% pred 101± 16 86 ± 17*
VC,% pred 103± 15 90 ± 20
FEV1/VC 0.78 ± 0.05 0.77 ± 0.11
FRC,% pred 100± 16 91 ± 25
ERV,% pred 91 ± 32 50 ± 31**
TLC,% pred 101± 11 97 ± 17
DLCO,% pred 86 ± 18 83 ± 19
Arterial blood gases
PaO2 (mmHg) 99 ± 24 88 ± 14
PaCO2 (mmHg) 39 ± 4 39± 4
6-minute walk test
6-minute walk distance (m) 524± 72 401 ± 107**
SpO2 at rest (%) 98 ± 2 97 ± 2
SpO2 after exertion (%) 94 ± 2 96 ± 2
Borg score at res 0.1 ± 0.4 1.1 ± 1.6
Borg score after 6MWT 3.9 ± 3 5.7 ± 2.1
Biological parameters
Hemoglobin (g/dL) 14.8 ± 1,3 13.7 ± 1,5*
NT pro-BNP (pg/mL) 97 ± 199 121± 301
CRP (mg/L) 5 ± 4,9 9.1 ± 7,4
Triglyceride (mmol/L) 1.9 ± 0,9 1.5 ± 0,8
Total cholesterol (mmol/L) 5.4 ± 1 4.7 ± 1
Fasting glucose (mmol/L) 5.3 ± 0,8 7.8 ± 3,3
Hba1c (%) 5.7 ± 0,6 6.8 ± 1,6
Data are expressed as number (%) or mean± SD; *p value<0.05, **p value< 0.01.
FEV1: expiratory volume in one second, pred: predicted value, VC: vital
capacity, FRC: functional residual capacity, ERV: expiratory reserve volume, TLC:
total lung capacity, DLCO: carbon monoxide diffusing capacity of the lung, NT
pro-BNP: N-terminal pro brain natriuretic peptide, CRP: serum C reactive
protein, HbA1c: glycated hemoglobin.
Normal biological parameters values were based on the normal values for our
laboratory: fasting glucose: 3.3 to 6.1 mmol/L; HbA1c: 4 to 6%; total
cholesterol: 3 to 5.2 mmol/L; triglycerides: 0.3 to 1.7 mmol/L; NT-pro
BNP< 300 pg/mL; CRP < 10 mg/L. Anemia was defined as hemoglobin
level < 13 g/dL in men and 12 g/dL in women.
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Results of spirometry, plethysmography and arterial blood
gases are shown in Table 4. Overall, the PFTs results
remained in the normal range for most of the patients, ex-
cept for ERV predicted values which were lower (ERV=56
±34%). There were an obstructive ventilatory disorder
defined by a FEV1/VC<0.7 in 5 patients (11%) with 5
patients (13%) exhibiting a mMRC≥ 1, a restrictive venti-
latory disorder defined by a TLC<80% in 5 patients (13%)
with 5 patients (16%) exhibiting a mMRC≥ 1, and a de-
crease in alveolar diffusion defined by DLCO<70% in 10
patients (26%) with 9 patients (28%) exhibiting a mMRC≥
1. Arterial blood gases at rest were in the normal range
with no hypoxemia < 70 mmHg and no significant
hypercapnia > 45 mmHg.
Biological parameters
Fifteen percent (n= 7) of patients presented anemia. All
patients had a hemoglobin level≥ 11 g/dL. Mean NT pro-
BNP was 117± 285 pg/mL. Four patients (10%) had a pro-
BNP>300 pg/mL.Forty-five percent of patients had a
fasting glucose level > 7 mmol/L, 51% a Hba1c > 6%, 29% a
triglyceride level≥ 1.7 mmol/L, 35% a total cholesterol
level > 5.2 mmol/L and 31% a CRP level > 10 mg/L.
Relationships between the mMRC scale and clinical
characteristics, PFTs and biological parameters
The comparisons between the mMRC scale and demo-
graphic, lung functional and biological parameters are
shown in Table 5. Subjects in the mMRC ≥ 1 group had
a higher BMI (p = 0.01) (Figure 1A), lower ERV
(p < 0.005) (Figure 1B), FEV1 (p < 0.05), covered distance
in 6MWT (p < 0.01) (Figure 1C) and Hb level (p < 0.05)
than subjects in the mMRC=0 group. Of note, there
was no association between the mMRC scale and age,
sex, smoking history, arterial blood gases, metabolic
parameters and the apnea/hypopnea index.
The relationships between the Borg scale after 6MWT
and demographic, lung functional and biological para-
meters were also analysed. The Borg score after 6MWT
was correlated with a higher BMI (correlation coefficient =
+0.44, p < 0.005) and a lower FEV1 (correlation coeffi-
cient = -0.33, p < 0.05). No relationship was found between
the Borg score after 6MWTand ERV or hemoglobin level.
The Borg score after 6MWT was correlated with a higher
fasting glucose (correlation coefficient = +0.46, p < 0.005)
whereas this parameter was not associated with the
mMRC scale (data not shown). We found no statistically
different change in Borg scale ratings of dyspnea from rest
to the end of the 6MWT between the two groups
(p= 0.39).
In this study, 45 consecutive obese subjects were spe-
cifically assessed for dyspnea in daily living using the
mMRC scale. Our study confirms the high prevalence ofdyspnea in daily living in obese subjects [2] with 84% of
patients exhibiting a mMRC scale ≥ 1 and 40% a mMRC
scale ≥ 2. Interestingly, the presence of dyspnea in daily
living (mMRC ≥ 1) was associated with a higher BMI and
a lower ERV, FEV1, distance covered in 6MWT and
Figure 1 Differences in Body Mass Index (BMI) (A), Expiratory reserve volume (ERV) (B) and 6-minute walk distance (C) between
non-dyspneic (modified Medical Research Council score = 0) and dyspneic (mMRC score≥ 1) subjects. *p < 0.05, **p < 0.01. A Wilcoxon test
was used.
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obese subjects was associated with a higher Borg score
after the 6MWT (data not shown).
The assessment of dyspnea in clinical practice is diffi-
cult. Regarding the mMRC scale, two versions of this scale
have been used, one with 5 grades [20] as used in this
study and an other with 6 grades [25] leading to some
confusion. Other scales have been also used to assess dys-
pnea [26]. Collet at al. [3], Ofir et al. [11] and El-Gamal
[27] et al provided some evidence to support the use of
the BDI, Oxygen cost diaphragm (OCD) and Chronic Re-
spiratory Disease Questionnaire (CRQ) to evaluate dys-
pnea in obesity. El-Gamal et al [27] demonstated the
responsiveness of the CRQ in obesity as they did measure-
ments before and after gastroplaty-induced weight loss
within the same subjects. The Baseline Dyspnea Index
(BDI) uses five grades (0 to 4) for 3 categories, functional
impairment, magnitude of task and magnitude of effort
with a total score from 0 to 12 [28]. The University of
California San Diego Shortness of Breath Questionnaire
comprises 24 items assessing dyspnea over the previous
week [29]. It must be pointed out that these scores are
much more time consuming than the mMRC scale and
are difficult to apply in clinical practice.
To our knowledge, the mMRC scale has not been
investigated in the assessment of dyspnea in daily living
in obese subjects without a coexisting pulmonary dis-
ease. The mMRC scale is an unidimensional scale
related to activities of daily living which is widely used
and well correlated with quality of life in chronic re-
spiratory diseases [20] such as chronic obstructive pul-
monary disease (COPD) [21] or idiopathic pulmonary
fibrosis [22]. The mMRC scale is easy-to-use and not
time consuming, based on five statements describing al-
most the entire range of dyspnea in daily living. Our
study provides evidence for the use of the mMRC scale
in the assessment of dyspnea in daily living in obese
subjects. Firstly, as expected, our results demonstrate
an association between the mMRC scale and the BMI
in the comparison between “dyspneic” and “nondyspneic” groups. Secondly, in our between-group com-
parisons, the mMRC scale was associated with pulmon-
ary functional parameters (lower ERV, FEV1 and
distance walked in 6MWT) which might be involved in
dyspnea in obesity. The reduction in ERV is the most
frequent functional respiratory abnormality reported in
obesity [6-8]. This decrease is correlated exponentially
with BMI and is mainly due to the effect of the abdom-
inal contents on diaphragm position [30]. While the
FEV1 might be slightly reduced in patients with severe
obesity, the FEV1/VC is preserved as seen in our study
[31]. The determination of the walking distance and the
Borg scale using the 6MWT is known to be a simple
method to assess the limitations of exercise capacity in
chronic respiratory diseases [23]. Two studies have
shown a good reproducibility of this test [32,33] but did
not investigate the relationships between the 6MWD
and dyspnea in daily living. Our study confirms the
feasibility of the 6MWD in clinical practice in obesity
and demonstrates an association between covered dis-
tance in 6MWT and the presence or the absence of
dyspnea in daily living assessed by the mMRC scale. It
must be pointed out that the 6MWT is not a standar-
dized exercise stimulus. Exercise testing using cycloerg-
ometer or the shuttle walking test could be of interest
to determine the relationships between the mMRC
scale and a standardize exercise stimulus. In our
between-group comparisons, BMI and FEV1 were asso-
ciated with the mMRC scale and correlated with the
Borg scale after 6MWT. Surprisingly, the ERV was
associated with the mMRC scale but not with the Borg
scale. Moreover, the fasting glucose was correlated with
the Borg scale after 6MWT but not associated with the
mMRC scale. Whether these differences are due to a
differential involvement of these parameters in dyspnea
in daily living and at exercise, or simply related to a
low sample size remains to be evaluated.
As type 2 diabetes, insulin resistance, metabolic syn-
drome [17-19], anemia and cardiac insufficiency have
been shown to be associated with lung function and/or
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dyspnea in daily living and biological parameters. A
mMRC scale ≥ 1 was associated with a lower hemoglobin
level. However, all patients had a hemoglobin
level > 11 g/dL and the clinical significance of the associ-
ation between dyspnea in daily living and a mildly lower
hemoglobin level has to be interpreted cautiously and
remains to be evaluated. Of note, we did not find any
associations between the mMRC scale and triglyceride,
total cholesterol, fasting glucose, HbA1C, CRP or NT
pro-BNP.
The strength of this study includes the assessment of
the relationships between the mMRC scale and multidi-
mensional parameters including exertional dyspnea
assessed by the Borg score after 6MWT, PFTs and bio-
logical parameters. The limitations of this pilot study
are as follows. Firstly, the number of patients included
is relatively low. This study was monocentric and did
not include control groups of overweight and normal
weight subjects. Due to the limited number of patients,
our study did not allow the analysis sex differences in
the perception of dyspnea. Secondly, we did not investi-
gate the relationships between the mMRC scale and
other dyspnea scales like the BDI which has been evalu-
ated in obese subjects and demonstrated some correla-
tions with lung function [3]. Thirdly, it would have
been interesting to assess the relationships between the
mMRC scale and cardio-vascular, neuromuscular and
psycho-emotional parameters which might be involved
in dyspnea. Assessing the relationships between health
related quality of life and dyspnea would also be useful.
Finally, fat distribution (eg Waist circumferences or
waist/hip ratios) has not been specifically assessed in
our study but might be assessed at contributing factor
to dyspnea. Despite these limitations, this pilot study
suggests that the mMRC scale might be of value in the
assessment of dyspnea in obesity and might be used as
a dyspnea scale in further larger multicentric studies. It
remains to be seen whether it is sensitive to changes
with intervention.
Conclusions
This pilot study investigated the potential use of the
mMRC scale in obesity. The differences observed be-
tween the “dyspneic” and the “non dyspneic” groups as
defined by the mMRC scale with respect to BMI, ERV,
FEV1 and distance covered in 6MWT suggests that the
mMRC scale might be an useful and easy-to-use tool to
assess dyspnea in daily living in obese subjects.
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